Current aspects of antiplatelet therapy

Authors: E.Z. Golukhova, M.N. Ryabinina

Company: A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Russian Academy of Medical Sciences


For citation: Golukhova EZ., Ryabinina MN. Current aspects of antiplatelet therapy. Kreativnaya kardiologiya. 2013; 1: 46-57 (in Russian)

Keywords: ischemic heart disease aspirin clopidogrel antiplatelet therapy

Download
Full text:  

 

Abstract

Dual antiplatelet therapy with the use of aspirin and clopidogrel in the presence of acute coronary syndrome (ACS) and at percutaneous coronary intervention (PCI) has reduced the risk of ischemic events. The more frequent attention has been paid recently to the variability of response to the antiplatelet therapy. High platelet reactivity increases the risk of ischemic events. The causes of resistance to antiplatelet agents are heterogeneous and multicomponent, i.e. clinical, cellular, and genetic. The clinical significance of genes polymorphism as a reason for resistance to antiplatelet therapy has remained at present not quite clear. The residual platelet activity on the background of dual antiplatelet therapy can be measured by various methods. There is no common opinion regarding the study technique as well as the criteria of treatment inefficiency. At present the platelet function has been assessed in clinical trials, but not in ordinary clinical practice. Additional research is required in order to settle the matter of routine assessment of platelet function and individual selection of antiplatelet therapy in accordance with the tests.

References

1. Ashley E.A., Neibauer J. Cardiology explained. London: Remedica; 2004: 45–76. 2. Карпов Ю.А., Самко А.Н., Буза В.В. Коронарная ангиопластика и стентирование. М.: МИА; 2010: 119–64. 3. Trenk D. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. J. Thromb. Haemost. 2013; 11–12. 4. Васильева Е.Ю., Касьянова О.В., Шпектор А.В. Уровень С-реактивного белка и эффективность терапии аспирином у пациентов с ишемической болезнью сердца. Кардиология. 2006; 45 (1): 66–7. 5. Деменьтьева И.И., Чарная М.А., Морозов Ю.А. Система гемостаза при операциях на сердце и магистральных сосудах. Нарушения, профилактика, коррекция. М.: ГЭОТАР-Медиа; 2009: 360–72. 6. Шамес А.Б. Атеросклероз: предупреждение тромбозов при хирургическом лечении стенотических поражений. М.: Бином; 2012: 1–86. 7. Grech E.D. (ed.) ABC of interventional cardiology. BMJ; 2004: 35–8. 8. Воробьева И.И., Рыжкова Е.В., Васильева Е.Ю., Шпектор А.В. Влияние системного воспаления на эффект антиагрегантной терапии у больных с острым коронарным синдромом. Креативная кардиология. 2012; 1: 5–14. 9. Васильева Е.Ю. Клинико-патогенетическое значение изменений тромбоцитарного гемостаза при ишемической болезни сердца: дис. … д-ра мед. наук. М.; 1992: 11–12. 10. Бузиашвили Ю.И., Самсонова H.H., Церетели Н.В. и др. Влияние коронарного стентирования на динамику показателей реактивного белка и функцию эндотелия у больных ИБС. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2007; 6: 247. 11. Lewis H.D., Davis J.W., Archibald D.G. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of veterans administration cooperative study. N. Engl. J. Med. 1985; 313: 1369–75. 12. Grosser T., Fries S., Lawson J.A., Kapoor Sh.C., Grant G.R., Fitzgerald G.A. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013; 127: 377–85. 13. Бурякина Т.А., Затейщиков Д.А. Место обратимых ингибиторов P2Y12 рецепторов при остром коронарном синдроме. Кардиологоия. 2012; 52 (4): 74–9. 14. Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial. N. Engl. J. Med. 2001; 345: 494–502. doi: 10.1056/NEJMoa010746. 15. Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527–33. doi: 10.1016/S0140- 6736(01)05701-4. 16. Steinhubl S.R., Berger P.B., Mann J.T. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–20. doi: 10.1001/jama.288.19.2411. 17. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005; 352: 1179–89. doi: 10.1056/NEJ-Moa050522. 18. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Effect of clopidogrel pre-treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294: 1224–32. doi: 10.1001/jama.294.10.1224. 19. Terpening С. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J. Am. Board. Fam. Med. 2009; 22: 51–6. 20. Бокарев И.Н., Попова Л.В., Козлова Т.В. Тромбозы и противотромботическая терапия в клинической практике. М.: МИА; 2009: 163–288. 21. Brar S.S., ten Berg J., Marcucci R. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 2011; 58 (19): 1945–53. 22. Gurbel P.A., Tantry U.S. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012; 125: 1276–87. 23. Syrbe G., Redlich H., Weidlich B. et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation. Clin. Appl. Thoromb. Hemost. 2001; 3: 209–13. 24. Mega J.L., Close S.L., Wiviott S.D. et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010; 376: 1312–9. 25. Becker R.C., Bassand J.P., Budaj A. et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 2011; 32: 2933–44. 26. Нeld C., Asenblad N., Bassand J.P. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery by pass surgery results from the PLATO (Platelet Inhibition and Patient Out-comes) trial. J. Am. Coll. Cardiol. 2011; 57: 672–84. 27. Mahaffey K.W., Wojdyla D.M., Carroll K. et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2011; 124: 544–5. 28. Сычев Д.А. Фармакогенетическое тестирование: клиническая интерпретация результатов. М.; 2011: 1–84. 29. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32: 2999–3054. 30. Wijns W., Kolh Ph., Danchin N. et al. Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2010; 31 (20): 2501–55. doi: 10.1093/eurheartj/ehq277. 31. Комаров А.Л., Панченко Е.П., Донников А.Е., Шахматов О.О., Джалилова Г.В., Илющенко Т.А. Факторы, определяю- щие клиническую эффективность клопидогрела и прогноз у больных со стабильной формой ишемической болезни серд- ца. Кардиология. 2011; 2: 8–18. 14

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery